The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) manufacturer ...

Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most ...

Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal polyps in ...

GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the group.

In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating ...

Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects ...

Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...

Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral ...

Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a ...

Coming out of Covid, the vaccine market appeared to experience a renaissance as the innovations of the pandemic unleashed new ...

California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...